Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 2011

View Archived Issues

Novel antifungal agents synthesized by Polichem

New dual IGF-I receptor/IR inhibitor is active in models of multiple myeloma

Ironwood Pharmaceuticals licenses Depomed's gastric retentive drug delivery technology

Scientists identify potential serum biomarker of neurofibromatosis type 1

Biogen Idec and Neurimmune disclose in vivo data on antibodies targeting Abeta peptides

Study investigates dyslipidemia-promoting mechanisms in obesity

Sanofi claims new antagonists of TNF receptor superfamily member 16

CNIO patents novel protein kinase pim inhibitors

ArQule prepares novel protein kinase inhibitors

Immunotec and Nova Southeastern University to test autism treatment

Adaptimmune's T-cell therapy enters pilot trial in synovial sarcoma

BioMarin reports preliminary results from phase I/II extension study of GALNS

Reply submitted to FDA's complete response letter on Bydureon NDA

Ribovax out-licenses SEBVI antibody technology

Enrollment begins in randomized phase II trial of NGR-hTNF in ovarian cancer

Data presented on long-term efficacy of raltegravir in HIV infection

Micell Technologies completes accrual in DESSOLVE II study

Enrollment complete in pivotal phase III SETTLE trial of safinamide mesilate

Yaupon Therapeutics files NDA for mechlorethamine gel

RegeneRx to commence phase II trial of RGN-259

FDA issues refuse to file letter in response to Eisai's NDA for perampanel

Lexicon Pharmaceuticals completes phase I trial of LX-1033

Otsuka vasopressin V2 receptor antagonist approved for hyponatremia in Canada

FDA awards orphan drug status to Diffusion Pharmaceuticals' TSC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...